Detalles de la búsqueda
1.
Extracellular Vesicle and Particle Biomarkers Define Multiple Human Cancers.
Cell
; 182(4): 1044-1061.e18, 2020 08 20.
Artículo
en Inglés
| MEDLINE | ID: mdl-32795414
2.
Pharmacokinetics of trastuzumab deruxtecan (T-DXd), a novel anti-HER2 antibody-drug conjugate, in HER2-positive tumour-bearing mice.
Xenobiotica
; 50(10): 1242-1250, 2020 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-32306807
3.
Safety, pharmacokinetics, and antitumour activity of trastuzumab deruxtecan (DS-8201), a HER2-targeting antibody-drug conjugate, in patients with advanced breast and gastric or gastro-oesophageal tumours: a phase 1 dose-escalation study.
Lancet Oncol
; 18(11): 1512-1522, 2017 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-29037983
4.
DS-8201a, a new HER2-targeting antibody-drug conjugate incorporating a novel DNA topoisomerase I inhibitor, overcomes HER2-positive gastric cancer T-DM1 resistance.
Int J Cancer
; 141(8): 1682-1689, 2017 10 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-28677116
5.
Bystander killing effect of DS-8201a, a novel anti-human epidermal growth factor receptor 2 antibody-drug conjugate, in tumors with human epidermal growth factor receptor 2 heterogeneity.
Cancer Sci
; 107(7): 1039-46, 2016 Jul.
Artículo
en Inglés
| MEDLINE | ID: mdl-27166974
6.
Novel antibody drug conjugates containing exatecan derivative-based cytotoxic payloads.
Bioorg Med Chem Lett
; 26(6): 1542-1545, 2016 Mar 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-26898815
7.
Wide application of a novel topoisomerase I inhibitor-based drug conjugation technology.
Bioorg Med Chem Lett
; 26(20): 5069-5072, 2016 10 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-27599744
8.
Calcitonin gene-related peptide is an important regulator of cutaneous immunity: effect on dendritic cell and T cell functions.
J Immunol
; 186(12): 6886-93, 2011 Jun 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-21551361
9.
Co-Clinical Study of [fam-] Trastuzumab Deruxtecan (DS8201a) in Patient-Derived Xenograft Models of Uterine Carcinosarcoma and Its Association with Clinical Efficacy.
Clin Cancer Res
; 29(12): 2239-2249, 2023 06 13.
Artículo
en Inglés
| MEDLINE | ID: mdl-36976261
10.
Visualization of Intratumor Pharmacokinetics of [fam-] Trastuzumab Deruxtecan (DS-8201a) in HER2 Heterogeneous Model Using Phosphor-integrated Dots Imaging Analysis.
Clin Cancer Res
; 27(14): 3970-3979, 2021 07 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-33980613
11.
A Novel HER3-Targeting Antibody-Drug Conjugate, U3-1402, Exhibits Potent Therapeutic Efficacy through the Delivery of Cytotoxic Payload by Efficient Internalization.
Clin Cancer Res
; 25(23): 7151-7161, 2019 12 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-31471314
12.
A HER2-Targeting Antibody-Drug Conjugate, Trastuzumab Deruxtecan (DS-8201a), Enhances Antitumor Immunity in a Mouse Model.
Mol Cancer Ther
; 17(7): 1494-1503, 2018 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-29703841
13.
DS-8201a, A Novel HER2-Targeting ADC with a Novel DNA Topoisomerase I Inhibitor, Demonstrates a Promising Antitumor Efficacy with Differentiation from T-DM1.
Clin Cancer Res
; 22(20): 5097-5108, 2016 Oct 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-27026201
14.
Calcitonin gene-related peptide regulates type IV hypersensitivity through dendritic cell functions.
PLoS One
; 9(1): e86367, 2014.
Artículo
en Inglés
| MEDLINE | ID: mdl-24466057
15.
Hypertension and dysregulated proinflammatory cytokine production in receptor activity-modifying protein 1-deficient mice.
Proc Natl Acad Sci U S A
; 104(42): 16702-7, 2007 Oct 16.
Artículo
en Inglés
| MEDLINE | ID: mdl-17923674
Resultados
1 -
15
de 15
1
Próxima >
>>